On September 1, 2020 Nordic Nanovector ASA (OSE: NANO) reported that its management team will present a corporate overview and host one-on-one meetings with investors at the Pareto Securities 11th Healthcare Conference, taking place 2nd-3rd September 2020 (Press release, Nordic Nanovector, SEP 1, 2020, View Source [SID1234564255]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will take place at 15:00hrs CEST on Thursday, 3rd September.

The company presentation will be available on Nordic Nanovector’s Investors and Media page at the same time.

On September 1, 2020 Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, reported that it has entered into a definitive agreement with ARK Investment Management, LLC (ARK Invest) and Alpha Capital Anstalt in connection with a registered direct offering of ordinary shares at a price per share of $1.70, for an aggregate cash consideration of $10 million (Press release, Evogene, SEP 1, 2020, View Source [SID1234564254]). Of the aggregate investment amount, ARK Invest, a leading technology investment firm, specializing in thematic investing in disruptive innovation, will invest $7 million and Alpha Capital Anstalt will invest $3 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evogene intends to use the net proceeds from the offering to further develop its and its subsidiaries’ product pipelines, to further enhance and expand its computational predictive biology platform, and for working capital and general corporate purposes.

The offering is expected to close on or before September 3, 2020, subject to customary closing conditions.

The shares of common stock offered in the registered direct offering described above are being offered by Evogene pursuant to its shelf registration statement on Form F-3 (File No.333-240249) previously filed and declared effective by the Securities and Exchange Commission (the "SEC") on August 10, 2020. The offering may be made only by means of a prospectus supplement and accompanying prospectus. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website.

This press release is for informational purposes only and should not be construed as investment advice and does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On September 1, 2020 Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") reported that the Company’s Board of Directors has implemented its previously disclosed succession plan and appointed Rainer M. Blair as President and Chief Executive Officer and a member of the Board of Directors effective today, September 1, 2020 (Press release, Danaher, SEP 1, 2020, View Source [SID1234564253]). Mr. Blair’s predecessor, Thomas P. Joyce, Jr., retired from these positions and will continue to support Danaher as a senior advisor through February 28, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 1, 2020 Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company, reported its newly discovered novel anti-human CCR8 mAbs (HBM1022) at the 16th PEGS Boston Summit (Press release, Harbour BioMed, SEP 1, 2020, View Source [SID1234564252]). HBM1022 was designed to target C-C chemokine receptor type 8 (CCR8), an extremely challenging G-protein coupled receptor (GPCR) with limited success in generating a cross-reactive antibodies in the past (cynomolgus and human). The poster was presented through a voice-over presentation at the 16th PEGS Boston Summit (from August 31 to September 4, 2020).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CCR8 is selectively up-regulated in tumor resident Treg cells in multiple solid tumors, but rarely observed on Treg cells in peripheral blood mononuclear cells (PBMCs) or other normal organs. High expression of CCR8 on Treg cells was first found to be associated with poor prognosis in breast cancer patients. These results suggest CCR8 could potentially be a promising therapeutic target.

HBM used a combination of next generation technologies including Single B Cell Technology with advanced phage display and hybridoma platforms to successfully develop the anti-CCR8 monoclonal antibody. It selectively targeted and depleted a subpopulation of tumor resident CCR8+ Tregs in the tumor microenvironment resulting in tumor growth inhibition, both as a single agent as well as in combination with anti-PD-1 antibody in preclinical setting. Furthermore, this antibody blocked the binding of CCL1 to CCR8 thereby inhibiting CCL1-induced suppressive function of TIL-Tregs.

"The ability to modulate the tumor micro-environment with a target like CCR8, either by itself or in combination with other molecules is an extremely promising approach. We are excited to develop this candidate further into a therapy that could address multiple tumor types in the future," Dr. Jingsong Wang said, the Founder, Chairman, and CEO of Harbour BioMed. "The success of generating antibodies against a difficult GPCR target further demonstrates the power and efficiency of HBM’s antibody discovery platforms," he added.

Poster Title:

Novel Monoclonal Antibodies (mAbs) Targeting Human CCR8 Provide Potential Candidates for Next Generation Cancer Immunotherapy

Please click the link below for the poster: View Source;sortByFields[0]=createdAt&sortByOrders[0]=-1

On September 1, 2020 Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, reported that it will participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference on Tuesday, September 15th (Press release, Legend Biotech, SEP 1, 2020, View Source [SID1234564251]). Frank Zhang, Chairman and Chief Executive Officer, and Ying Huang, Chief Financial Officer, will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This webcast will be available to investors and other interested parties by accessing the Legend Biotech website at View Source